Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

130.69USD
18 Jan 2019
Change (% chg)

$1.60 (+1.24%)
Prev Close
$129.09
Open
$130.00
Day's High
$131.18
Day's Low
$129.47
Volume
4,326,254
Avg. Vol
2,797,578
52-wk High
$148.97
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson Completes Acquisition Of CiZ Holdings Co Ltd
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Ci:z Holdings Co Ltd <4924.T>::JOHNSON & JOHNSON COMPLETES ACQUISITION OF CI:Z HOLDINGS CO., LTD..J&J - ANY EPS IMPACT OF DEAL WILL BE INCLUDED IN 2019 GUIDANCE PROVIDED ON CO'S Q4 2018 EARNINGS CALL.  Full Article

Actelion Ltd Receives Complete Response Letter From U.S. FDA
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Actelion Ltd ::ACTELION RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR OPSUMIT® (MACITENTAN) SUPPLEMENTAL NEW DRUG APPLICATION.ACTELION RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR OPSUMIT® (MACITENTAN) SUPPLEMENTAL NEW DRUG APPLICATION.ACTELION PHARMACEUTICALS LTD - CRL INDICATES ADDITIONAL DATA ARE NEEDED TO EVALUATE USE OF OPSUMIT IN TREATMENT OF CTEPH.  Full Article

Winterlight Labs And J&J Innovation To Develop Digital Biomarker For Diagnosis Of Early Stage Alzheimer's
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Winterlight Labs Inc::WINTERLIGHT LABS, INC. ENTERS COLLABORATION WITH JOHNSON & JOHNSON INNOVATION TO DEVELOP A DIGITAL BIOMARKER FOR DIAGNOSIS OF EARLY STAGE ALZHEIMER'S DISEASE.WINTERLIGHT LABS - ENTERED A COLLABORATION WITH JANSSEN PHARMACEUTICALS, INC.  Full Article

Johnson & Johnson Announces Quarterly Cash Dividend Of $0.90 Per Share
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR FIRST QUARTER 2019.SETS QUARTERLY CASH DIVIDEND OF $0.90PER SHARE.  Full Article

Johnson & Johnson CEO defends its talc on CNBC
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Johnson & Johnson ::CEO Gorsky says its studies show there’s no causation between baby powder and ovarian cancer or asbestos-related disease.  Full Article

Health Canada Approves Darzalex For Newly Diagnosed Patients With Multiple Myeloma Who Are Transplant Ineligible
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Janssen Inc::HEALTH CANADA APPROVES DARZALEX® (DARATUMUMAB) FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE.JANSSEN - HEALTH CANADA APPROVAL OF DARZALEX FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE MARKS ITS THIRD INDICATION.  Full Article

Janssen Submits Supplemental New Drug Application To FDA For XARELTO (Rivaroxaban) To Prevent Venous Thromboembolism (VTE) In Acute Medically Ill Patients
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA FOR XARELTO® (RIVAROXABAN) TO PREVENT VENOUS THROMBOEMBOLISM (VTE) IN ACUTE MEDICALLY ILL PATIENTS.JANSSEN - SNDA FOR XARELTO BASED ON COMBINED DATA FROM PHASE 3 MAGELLAN AND MARINER TRIALS.  Full Article

Janssen Signs Results-Based Contract With Oklahoma Health Care Authority For Its Long-Acting Injectable Schizophrenia Medicines
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Johnson & Johnson ::JANSSEN SIGNS RESULTS-BASED CONTRACT WITH OKLAHOMA HEALTH CARE AUTHORITY (OHCA) FOR ITS LONG-ACTING INJECTABLE SCHIZOPHRENIA MEDICINES.JANSSEN - ARRANGEMENT WITH OHCA FOCUSED ON ENABLING USE OF INVEGA SUSTENNA AND INVEGA TRINZA EARLIER IN TREATMENT OF ADULTS WITH SCHIZOPHRENIA.  Full Article

St. Joe Co And Johnson & Johnson (dBa Busy Bee) Announce Plans For Store In Panama City Beach
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - St. Joe Co ::THE ST. JOE COMPANY AND JOHNSON & JOHNSON (DBA BUSY BEE) ANNOUNCE PLANS FOR A BUSY BEE BRANDED FUEL STATION AND CONVENIENCE STORE IN PANAMA CITY BEACH.ST. JOE CO - PROJECT IS EXPECTED TO COMMENCE CONSTRUCTION MID 2019.  Full Article

Protagonist Therapeutics Announces New Development Candidate Pn-10943 For Treatment Of Inflammatory Bowel Disease
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS ANNOUNCES NEW DEVELOPMENT CANDIDATE PN-10943 FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE.PROTAGONIST THERAPEUTICS INC - PHASE 1 STUDY OF PN-10943 TO BEGIN IN DECEMBER 2018.PROTAGONIST THERAPEUTICS INC - PN-10943 TO REPLACE PTG-100 IN CLINICAL DEVELOPMENT FOR INFLAMMATORY BOWEL DISEASE.PROTAGONIST THERAPEUTICS INC - S CASH RUNWAY EXTENDED BY ADDITIONAL SIX MONTHS TO END OF 2020.PROTAGONIST THERAPEUTICS - PHARMACODYNAMIC READOUTS OF BLOOD RECEPTOR OCCUPANCY EXPECTED IN H1 2019 FROM PHASE 1 STUDY OF PN-10943.PROTAGONIST THERAPEUTICS INC - PRIMARY ENDPOINTS FOR STUDY ARE SAFETY AND TOLERABILITY OF PN-10943.PROTAGONIST THERAPEUTICS INC - EXPECT TO ADVANCE PTG-200 IN A PHASE 2 CROHN'S STUDY WITH JANSSEN.  Full Article

UPDATE 1-AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

Jan 18 AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.